Simvastatin Tablet, Film Coated
Product Images NDC 71335-1891

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Simvastatin (NDC 71335-1891). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Footnote For Table 3 (Footnote For Table 3)

This document discusses the results of a chemical assay related to the effects of certain inhibitors (such as Ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone) on the drug Simvastatin. It also mentions the presence of Simvastatin acid, as well as the lack of research regarding the impact of different amounts of grapefruit juice on Simvastatin pharmacokinetics. The document also provides information on the dosages and timing of grapefruit juice and Simvastatin administration during the study.*

FDA Label Image

Label (Lbl713351891)

This appears to be a label for a prescription bottle of Simvastatin, a medication used to control cholesterol levels. The label provides information such as the strength of each tablet (20mg), storage instructions, and the expiration date. The medication is to be kept out of reach of children.*

FDA Label Image

Figure 9 (Simvastatin 10)

FDA Label Image

Table2 (Simvastatin 2)

This is a table showing the adverse reactions reported by patients treated with Simvastatin and Placebo. The table includes the percentage of patients experiencing adverse reactions in various body systems. Some of the adverse reactions reported include edema and swelling, abdominal pain, atrial fibrillation, constipation, myalgia, headache, insomnia, vertigo, bronchitis, sinusitis, eczema, and urinary tract infection.*

FDA Label Image

Structure (Simvastatin 3)

FDA Label Image

Table 3 (Simvastatin 4)

FDA Label Image

Table 4 (Simvastatin 5)

FDA Label Image

Figure 5 (Simvastatin 6)

This is a medical study analyzing the efficacy of Simvastatin in preventing major vascular and coronary events in patients with or without previous cardiovascular health issues. The study involved a total of 20,858 patients, with varying degrees of peripheral and coxaezovascular diseases. The text is mostly presented in the form of a table, which includes data on the number of patients with and without cHD, their respective treatments with Simvastatin and Placebo, and their corresponding risk ratios for major vascular and coronary events.*

FDA Label Image

Figure 6 (Simvastatin 7)

FDA Label Image

Figure 7 (Simvastatin 8)

FDA Label Image

Figure 8 (Simvastatin 9)

FDA Label Image

Table 1 (Table1)

The text is discussing drug interactions that are associated with an increased risk of myopathy/rhabdomyolysis. It lists a number of interacting agents and provides prescribing recommendations for each. The interactions include strong CYP3A4 inhibitors, HIV protease inhibitors, niacin, verapamil, diltiazem, amiodarone, and others. Patients with HOFH are cautioned not to exceed certain doses, and individuals taking certain medications are advised to avoid grapefruit juice. The last line is an error and is not available.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.